Abstract
The muscle myosins are hexomeric proteins consisting of two heavy chains and two pairs of light chains, the latter called essential (ELC) and regulatory (RLC). The light chains stabilize the long alpha helical neck of the myosin head. Their function in striated muscle, however, is only partially understood. We report here the identification of distinct missense mutations in a skeletal/ventricular ELC and RLC, each of which are associated with a rare variant of cardiac hypertrophy as well as abnormal skeletal muscle.We show that myosin containing the mutant ELC has abnormal function, map the mutant residues on the three–dimensional structure of myosin and suggest that the mutations disrupt the stretch activation response of the cardiac papillary muscles.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Huxley, A.R. Muscle structure and theories of contraction. Prog. Biophys. Biophys. Chem. 7, 255–318 (1957).
Huxley, H.E. The mechanism of muscular contraction. Science 164, 1356–1366 (1969).
Rayment, I. et al. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261, 50–58 (1993).
Xie, X. et al. Structure of the regulatory domain of scallop myosin at 2.8 Å resolution. Nature 368, 306–312 (1994).
Houdusse, A. & Cohen, C. Structure of the regulatory domain of scallop myosin at 2 resolution:implications for regulation. Structure 4, 21–32 (1996).
Fisher, A.J. et al. Structural studies of myosin: nucleotide complexes: a revised model for the molecular basis of muscle contraction. Biophys. J. 68, 19s–28s (1995).
Irving, M. et al. Tilting of the light-chain region of myosin during step length changes and active force generation in skeletal muscle. Nature 375, 748–751 (1995).
Whittaker, M. et al. Å 35-A movement of smooth muscle myosin on ADP release. Nature 378, 748–751 (1995).
Eden, D. & Highsmith, S. Myosin cross-bridge elasticity. Biophys. J. 68, 372s–373s (1994).
Morano, I. & Ruegg, J.C. Calcium sensitivity of myofilaments in cardiac muscle- effect of myosin phosphorylation. Basic Res. Cardiol. 81, 17s–23s
Persechini, A., Stull, J.T. & Cooke, R. The effect of myosin phosphorylation on the contractile properties of skinned rabbit skeletal muscle fibers. J. Biol. Chem. 260, 7951–7954 (1985).
Sweeney, H.L. & Stull, J.T. Phosphorylation of myosin in permeabilized mammalian cardiac and skeletal muscle cells. Am. J. Physiol. 250, C657–C660 (1986).
Payment, I., Holden, H.M., Sellers, J., Fananapazir, L. & Epstein, N.D Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci.USA 92, 3864–3868
Maron, B.J. & Epstein, S.E. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J. Cardiol. 43, 1242–1244 (1979).
Thierfelder, F. et al. α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701–712 (1994).
Bonne, G. et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nature Genet. 11, 438–440 (1995).
Watkins, H. et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nature Genet. 11, 434–437 (1995).
Cuda, G., Fananapazir, L., Zhu, W.-Z., Sellers, J. & Epstein, N.D. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J. Clin. Invest. 91, 2861–2865 (1993).
Perryman, M.B. et al. Expression of a missense mutation in the mRNA for b-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. J. Clin. Invest. 90, 271–277 (1992).
Pavlakis, S.G., Rowland, L.R., DeVivo, D.C., Bonilla, E. & DiMauro, S. in Advances in Contemporary Neurology (ed. Plum, F.) 95–133 (FA. Davis, Philadelphia, 1988).
Steiger, G.J. Stretch activation and myogenic oscillation of isolated contractile structures of heart muscle. Pflugers Arch. 330, 347–361 (1971).
Tohtong, R., Yamashita, H., Graham, M., Haeberle, J., Simcox, A. & Maughan, D. Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain. Nature 374, 650–653 (1995).
Fodor, W.L. Human ventricular/slow twitch myosin alkalai light chain gene characterization, sequence, and chromosomal location. J. Biol. Chem. 264, 2143–2149 (1989).
Macera, M.J., Szabo, R., Wadgaonkar, R., Siddiqui, M.A.G. & Verma, R.S. Localization of the gene coding for ventricular myosin regulatory light chain (MYL2) to human chromosome 12q23-q24. Genomics 13, 829–831 (1992).
Epstein, N.D., Cohn, G.M., Cyran, F. & Fananapazir, L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a Leu908Val and an Arg403Gln mutation. Circulation 86, 345–352 (1992).
Fananapazir, L. & Epstein, N.D. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Circulation 89, 22–32 (1994).
Romeo, G. & McKusick, V.A. Phenotypic diversity, allelic series and modifier genes. Nature Genet. 7, 451–453 (1994).
Umemoto, S. & Sellers, J.R. Characterization of in vitro motility assays using smooth muscle and cytoplasmic myosins. J. Biol. Chem. 265, 14864–14869 (1990).
Spudich, J.A. How molecular motors work. Nature 372, 515–518 (1994).
Lankford, E.B., Epstein, N.D., Hananapazir, L. & Sweeney, H.L. Abnormal contractile properties of muscle fibers expressing β-myosin chain mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 95, 1409–1414 (1995).
Fananapazir, L., Dalakas, M.C., Cohn, G. & Epstein, N.D. Missense mutations in the β-myosin heavy chain cause central core disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 90, 3993–3997 (1993).
VanBuren, P., Waller, G.S., Harris, D.E., Trybus, K.M., Warshaw, D.M. & Lowey, S. The essential light chain is required for full force production by skeletal muscle myosin. Proc. Natl. Acad. Sci. USA 91, 12403–12407 (1994).
Huxley, A.F. & Simmons, R.M. Proposed mechanism of force generation in striated muscle. Nature 233, 533–538 (1972).
Milligan, R.A., Whittaker, M. & Safer, D. Molecular structure of F-actin and location of surface binding sites. Nature 348, 217–221 (1990).
Trayer, I.P., Trayer, H.R. & Levine, B.A. Evidence that the N-terminal region of the A-1 light chain of myosin interacts directly with the C-terminal region of actin. Eur. J. Biochem. 164, 259–266 (1987).
Eisenberg, E. & Greene, L.E. The relation of muscle biochemistry to muscle physiology. Annu. Rev. Physiol. 42, 293–309 (1980).
Hill, T.L., Transduction in Biology (Academic Press, N. Y., (1977).
Steiger, G.J. in Insect Flight Muscle (ed. Tregear, R.T.). 221–268 (North-Holland, Amsterdam, 1977).
Pringle, J.W.S. Stretch activation of muscle: function and mechanism. Proc. R. Soc. Lond. B. 201, 107–130 (1978).
Maron, B.J., Gottdiener, J.S. & Epstein, S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. Am. J. Cardiol. 48, 418–428 (1981).
Du, Y. & Sarkar, S., Genbank Accession♯ L01652 (1993).
Lathrop, G.M. & Lalouel, J.M. Easy calculations of lod scores andgenetic risks on small computers. Am. J. Hum. Gen. 36, 460–465 (1984).
Eisenberg, E. & Keilley, W.W. Troponin-tropomyosin complex. J. Biol. Chem. 249, 4742–4744 (1974).
Devereux, J., Haeberli, P. & Smithies, O. A comprehensive set of sequence analysis programs for the VAX. Nucl. Acids Res. 12, 387–395 (1984).
Kraulis, R.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structure. J. Appl. Crystallogr. 24, 946–950 (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Poetter, K., Jiang, H., Hassanzadeh, S. et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 13, 63–69 (1996). https://doi.org/10.1038/ng0596-63
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0596-63
This article is cited by
-
Mechanisms of Sarcomere Protein Mutation-Induced Cardiomyopathies
Current Cardiology Reports (2023)
-
Regulation of myosin light-chain phosphorylation and its roles in cardiovascular physiology and pathophysiology
Hypertension Research (2022)
-
Insights into myosin regulatory and essential light chains: a focus on their roles in cardiac and skeletal muscle function, development and disease
Journal of Muscle Research and Cell Motility (2020)
-
From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies
Current Heart Failure Reports (2019)
-
Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains
Pflügers Archiv - European Journal of Physiology (2019)